OpenLB
Open Library of Bioscience
Advanced Search
International journal of molecular sciences
Jun 23, 2021;22 (13):

Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Fabrice Tolle, Viktor Umansky, Jochen Utikal, Stephanie Kreis, Sabrina Bréchard
Author Information
  1. Fabrice Tolle: Department of Life Sciences and Medicine, University of Luxembourg, L-4367 Belvaux, Luxembourg. ORCID
  2. Viktor Umansky: Skin Cancer Unit, German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany. ORCID
  3. Jochen Utikal: Skin Cancer Unit, German Cancer Research Center (DKFZ), 69121 Heidelberg, Germany. ORCID
  4. Stephanie Kreis: Department of Life Sciences and Medicine, University of Luxembourg, L-4367 Belvaux, Luxembourg.
  5. Sabrina Bréchard: Department of Life Sciences and Medicine, University of Luxembourg, L-4367 Belvaux, Luxembourg.
PMID: 34201758 DOI: 10.3390/ijms22136744

Abstract

Neutrophils-once considered as simple killers of pathogens and unexciting for cancer research-are now acknowledged for their role in the process of tumorigenesis. Neutrophils are recruited to the tumor microenvironment where they turn into tumor-associated neutrophils (TANs), and are able to initiate and promote tumor progression and metastasis. Conversely, anti-tumorigenic properties of neutrophils have been documented, highlighting the versatile nature and high pleiotropic plasticity of these polymorphonuclear leukocytes (PMN-L). Here, we dissect the ambivalent roles of TANs in cancer and focus on selected functional aspects that could be therapeutic targets. Indeed, the critical point of targeting TAN functions lies in the fact that an immunosuppressive state could be induced, resulting in unwanted side effects. A deeper knowledge of the mechanisms linked to diverse TAN functions in different cancer types is necessary to define appropriate therapeutic strategies that are able to induce and maintain an anti-tumor microenvironment.

Keywords

immunotherapy metastasis neutrophils tumorigenesis

References

  1. Nature. 2015 Jun 18;522(7556):349-53 [PMID: 25985180]
  2. Sci Rep. 2019 Dec 23;9(1):19673 [PMID: 31873162]
  3. Mol Cancer. 2020 Aug 6;19(1):120 [PMID: 32762681]
  4. Cancer Gene Ther. 2021 Feb;28(1-2):5-17 [PMID: 32457487]
  5. Carcinogenesis. 2008 Oct;29(10):2035-43 [PMID: 18689872]
  6. Science. 2018 Sep 28;361(6409): [PMID: 30262472]
  7. Eur J Cell Biol. 2011 Jun-Jul;90(6-7):476-83 [PMID: 21439673]
  8. Blood. 1994 Sep 15;84(6):1737-46 [PMID: 7521686]
  9. Clin Transl Oncol. 2017 Jun;19(6):711-717 [PMID: 27909873]
  10. Adv Mater. 2018 May;30(22):e1706245 [PMID: 29577477]
  11. Lung Cancer. 2017 Jul;109:28-35 [PMID: 28577946]
  12. J Immunother Cancer. 2018 Jul 16;6(1):74 [PMID: 30012216]
  13. Oncoimmunology. 2015 Jun 24;5(2):e1062208 [PMID: 27057428]
  14. Clin Cancer Res. 2017 Sep 1;23(17):5187-5201 [PMID: 28698201]
  15. Oncotarget. 2016 May 10;7(19):27676-88 [PMID: 27050283]
  16. Nat Commun. 2018 Nov 14;9(1):4783 [PMID: 30429478]
  17. Semin Immunol. 2018 Feb;35:19-28 [PMID: 29254756]
  18. Mutat Res. 2015 Mar;773:9-15 [PMID: 25705119]
  19. J Immunol. 2018 Jan 15;200(2):422-431 [PMID: 29311384]
  20. Sci Immunol. 2019 Oct 18;4(40): [PMID: 31628161]
  21. Biochem Pharmacol. 2009 Sep 1;78(5):504-13 [PMID: 19433064]
  22. J Exp Med. 2021 Apr 5;218(4): [PMID: 33566112]
  23. Cancer Immunol Immunother. 2017 Jan;66(1):77-89 [PMID: 27796477]
  24. Immunol Rev. 2016 Sep;273(1):329-43 [PMID: 27558344]
  25. Trends Immunol. 2019 Jul;40(7):584-597 [PMID: 31153737]
  26. J Immunol. 2008 Oct 1;181(7):4666-75 [PMID: 18802069]
  27. FASEB J. 2018 Jun 20;:fj201800691R [PMID: 29924943]
  28. Anat Rec A Discov Mol Cell Evol Biol. 2003 Sep;274(1):778-84 [PMID: 12923888]
  29. J Immunol. 2011 Jan 1;186(1):242-54 [PMID: 21135163]
  30. EMBO Mol Med. 2013 Sep;5(9):1311-21 [PMID: 23922331]
  31. Oncoimmunology. 2017 Aug 16;6(11):e1356965 [PMID: 29147615]
  32. Biochem Biophys Res Commun. 2017 Nov 4;493(1):592-597 [PMID: 28867179]
  33. FASEB J. 2015 Jul;29(7):3003-13 [PMID: 25837581]
  34. Science. 2017 Dec 1;358(6367):1202-1206 [PMID: 29191910]
  35. Biochem Biophys Res Commun. 2015 Apr 24;460(1):40-9 [PMID: 25998732]
  36. Cancers (Basel). 2021 Feb 10;13(4): [PMID: 33578808]
  37. Clin Cancer Res. 2018 Oct 1;24(19):4834-4844 [PMID: 29914893]
  38. Redox Biol. 2021 Jun;42:101891 [PMID: 33583736]
  39. J Cell Sci. 2012 Feb 1;125(Pt 3):649-61 [PMID: 22389402]
  40. J Exp Med. 2008 Sep 29;205(10):2235-49 [PMID: 18809714]
  41. Cancer Res. 2010 Jan 1;70(1):99-108 [PMID: 19996287]
  42. Nat Rev Clin Oncol. 2017 Jul;14(7):399-416 [PMID: 28117416]
  43. Blood. 2013 Oct 17;122(16):2784-94 [PMID: 24009232]
  44. J Immunother Cancer. 2020 Sep;8(2): [PMID: 32907925]
  45. J Pathol. 2018 Nov;246(3):300-310 [PMID: 30062795]
  46. Sci Transl Med. 2016 Oct 19;8(361):361ra138 [PMID: 27798263]
  47. Inflamm Res. 2018 Oct;67(10):801-812 [PMID: 30083975]
  48. J Physiol. 2018 Jul;596(14):2699-2708 [PMID: 29441588]
  49. Clin Cancer Res. 2019 May 1;25(9):2887-2899 [PMID: 30705034]
  50. Trends Immunol. 2019 Jul;40(7):565-583 [PMID: 31160207]
  51. Trends Immunol. 2016 Jan;37(1):41-52 [PMID: 26700397]
  52. Adv Exp Med Biol. 2017;981:205-214 [PMID: 29594863]
  53. Front Oncol. 2019 Nov 15;9:1146 [PMID: 31799175]
  54. Neoplasia. 2014 Oct 23;16(10):771-88 [PMID: 25379015]
  55. J Immunol. 2004 Mar 1;172(5):2731-8 [PMID: 14978070]
  56. J Leukoc Biol. 1999 Oct;66(4):549-56 [PMID: 10534107]
  57. J Immunol. 2001 Jan 1;166(1):624-32 [PMID: 11123346]
  58. Nat Rev Cancer. 2020 Sep;20(9):485-503 [PMID: 32694624]
  59. Cell. 1998 Mar 6;92(5):645-56 [PMID: 9506519]
  60. PLoS One. 2013 Dec 05;8(12):e82282 [PMID: 24340014]
  61. Nat Med. 2010 Feb;16(2):219-23 [PMID: 20081861]
  62. Exp Cell Res. 2006 Jan 15;312(2):184-97 [PMID: 16297907]
  63. J Leukoc Biol. 2020 Feb;107(2):285-297 [PMID: 31841231]
  64. Arch Immunol Ther Exp (Warsz). 2018 Feb;66(1):21-30 [PMID: 28560557]
  65. Eur J Immunol. 2019 Feb;49(2):221-227 [PMID: 30629284]
  66. Eur J Pharmacol. 2009 Dec 25;625(1-3):73-83 [PMID: 19835859]
  67. J Clin Invest. 2010 Jul;120(7):2423-31 [PMID: 20516641]
  68. Oncoimmunology. 2016 Feb 18;5(5):e1134073 [PMID: 27467952]
  69. Cancer Res. 2018 May 15;78(10):2680-2690 [PMID: 29490946]
  70. Nat Nanotechnol. 2017 Jul;12(7):692-700 [PMID: 28650441]
  71. J Leukoc Biol. 2004 Jul;76(1):169-75 [PMID: 15075348]
  72. Science. 2004 Mar 5;303(5663):1532-5 [PMID: 15001782]
  73. Sci Rep. 2020 Sep 28;10(1):15874 [PMID: 32981934]
  74. Cancer Immunol Immunother. 2009 Jan;58(1):49-59 [PMID: 18446337]
  75. Sci Rep. 2018 Sep 5;8(1):13285 [PMID: 30185911]
  76. Growth Factors. 2005 Mar;23(1):33-41 [PMID: 16019425]
  77. Trends Immunol. 2012 Mar;33(3):119-26 [PMID: 22277903]
  78. J Clin Invest. 2012 Sep;122(9):3127-44 [PMID: 22922255]
  79. Mol Carcinog. 2019 Sep;58(9):1648-1655 [PMID: 31140647]
  80. Cancer Res. 2007 Sep 1;67(17):8121-30 [PMID: 17804724]
  81. Mol Cancer Res. 2011 Feb;9(2):133-48 [PMID: 21228116]
  82. Int J Biol Sci. 2018 Jan 12;14(2):111-123 [PMID: 29483830]
  83. Sci Rep. 2019 Nov 27;9(1):17732 [PMID: 31776393]
  84. Eur J Cancer. 1996 Apr;32A(4):734-5 [PMID: 8695282]
  85. Cell Mol Immunol. 2019 Jan;16(1):19-27 [PMID: 29572545]
  86. Ann N Y Acad Sci. 2014 Jun;1319:47-65 [PMID: 24965257]
  87. PLoS One. 2014 Jul 11;9(7):e101848 [PMID: 25014230]
  88. Nat Rev Clin Oncol. 2019 Sep;16(9):563-580 [PMID: 31092901]
  89. J Physiol. 2018 Jul;596(14):2681-2698 [PMID: 29368348]
  90. Cancer Res. 2006 Jan 15;66(2):605-12 [PMID: 16423985]
  91. Sci Rep. 2020 Feb 6;10(1):1983 [PMID: 32029833]
  92. Eur J Clin Invest. 2018 Nov;48 Suppl 2:e12952 [PMID: 29772063]
  93. Nat Med. 2014 Jun;20(6):676-81 [PMID: 24859530]
  94. Nat Commun. 2016 Mar 21;7:11037 [PMID: 26996437]
  95. Blood. 2002 Apr 15;99(8):2997-3004 [PMID: 11929792]
  96. Cell Calcium. 2018 Sep;74:160-167 [PMID: 30086406]
  97. Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13076-81 [PMID: 22826226]
  98. Front Immunol. 2018 Mar 13;9:447 [PMID: 29593718]
  99. Cancers (Basel). 2019 Sep 07;11(9): [PMID: 31500300]
  100. J Leukoc Biol. 2007 Dec;82(6):1375-81 [PMID: 17709402]
  101. J Immunol. 2011 Feb 15;186(4):2182-91 [PMID: 21239714]
  102. Cell Death Discov. 2015 Nov 30;1:15056 [PMID: 27551482]
  103. FEBS Lett. 2011 Jan 21;585(2):440-6 [PMID: 21192933]
  104. FEBS J. 2018 Dec;285(23):4316-4342 [PMID: 29851227]
  105. Nat Commun. 2020 Oct 9;11(1):5120 [PMID: 33037194]
  106. Biochim Biophys Acta. 2008 Feb;1783(2):297-311 [PMID: 18060880]
  107. Blood. 2004 Apr 15;103(8):3148-57 [PMID: 15070697]
  108. Cell Calcium. 2019 Jun;80:1-7 [PMID: 30921687]
  109. FEBS Lett. 2010 Jul 16;584(14):3193-7 [PMID: 20541553]
  110. Biol Chem. 1996 Nov;377(11):689-93 [PMID: 8960369]
  111. Cancer Biol Med. 2020 Feb 15;17(1):32-43 [PMID: 32296575]
  112. Cancer Cell. 2009 Sep 8;16(3):183-94 [PMID: 19732719]
  113. Br J Cancer. 2019 Jan;120(1):16-25 [PMID: 30413826]
  114. Cancer Immunol Immunother. 2019 Apr;68(4):645-660 [PMID: 30003321]
  115. Steroids. 2018 May;133:96-101 [PMID: 29155217]
  116. Blood. 2000 Oct 15;96(8):2673-81 [PMID: 11023497]
  117. Trends Cancer. 2017 Feb;3(2):149-160 [PMID: 28718445]
  118. Oncogene. 2014 Jun 5;33(23):3054-63 [PMID: 23851508]
  119. Nat Commun. 2015 Mar 26;6:6673 [PMID: 25809117]
  120. Am J Physiol Lung Cell Mol Physiol. 2013 Mar 1;304(5):L342-9 [PMID: 23316068]
  121. PLoS One. 2013;8(1):e55818 [PMID: 23383287]
  122. Cancer Res. 2011 Feb 1;71(3):998-1008 [PMID: 21245094]
  123. Cancer Res. 2012 Aug 15;72(16):3919-27 [PMID: 22751466]
  124. Expert Rev Mol Diagn. 2018 Jul;18(7):675-683 [PMID: 29707981]
  125. JCI Insight. 2020 Aug 6;5(15): [PMID: 32584791]
  126. Curr Opin Genet Dev. 2008 Feb;18(1):11-8 [PMID: 18308558]
  127. J Clin Invest. 2013 Jul 1;: [PMID: 23863628]
  128. PLoS One. 2011;6(12):e29318 [PMID: 22195044]
  129. Trends Immunol. 2019 Apr;40(4):310-327 [PMID: 30890304]
  130. Nat Commun. 2016 Jul 06;7:12150 [PMID: 27381735]
  131. Int J Biol Sci. 2018 Nov 28;14(14):2103-2113 [PMID: 30585273]
  132. Oncotarget. 2017 Aug 18;8(42):72818-72834 [PMID: 29069828]
  133. Clin Cancer Res. 2019 Mar 15;25(6):1867-1879 [PMID: 30446590]
  134. J Clin Invest. 1961 Jun;40:989-95 [PMID: 13684958]
  135. J Cell Biol. 2007 Jan 15;176(2):231-41 [PMID: 17210947]
  136. J Leukoc Biol. 2017 Aug;102(2):343-349 [PMID: 28264904]
  137. Immunity. 2014 Jul 17;41(1):49-61 [PMID: 25035953]
  138. Semin Cancer Biol. 2018 Apr;49:37-43 [PMID: 28811077]
  139. Sci Immunol. 2016 Aug;1(2): [PMID: 28417112]
  140. Biochim Biophys Acta. 2015 Dec;1852(12):2706-11 [PMID: 26435083]
  141. Cancer Res. 2008 Jul 1;68(13):5439-49 [PMID: 18593947]
  142. Curr Opin Immunol. 2018 Apr;51:154-161 [PMID: 29614426]
  143. Matrix Biol. 2014 Feb;34:22-32 [PMID: 24513040]
  144. Trends Immunol. 2019 Mar;40(3):228-242 [PMID: 30777721]
  145. Nat Rev Immunol. 2021 Feb 1;: [PMID: 33526920]
  146. Nat Cell Biol. 2006 Dec;8(12):1369-75 [PMID: 17128264]
  147. Carcinogenesis. 2010 Sep;31(9):1541-51 [PMID: 20622003]
  148. Nat Cell Biol. 2008 Nov;10(11):1349-55 [PMID: 18820689]
  149. Am J Pathol. 2001 Oct;159(4):1405-14 [PMID: 11583968]
  150. Semin Immunol. 2016 Apr;28(2):187-96 [PMID: 27067179]
  151. Mol Cancer Ther. 2020 Jul;19(7):1530-1538 [PMID: 32371579]
  152. Semin Cancer Biol. 2013 Jun;23(3):159-70 [PMID: 23410636]
  153. BMC Med. 2020 Nov 20;18(1):360 [PMID: 33213430]
  154. Blood. 2017 Sep 28;130(13):1565-1577 [PMID: 28724541]
  155. Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721 [PMID: 27649880]
  156. J Immunol. 2013 Apr 1;190(7):3815-23 [PMID: 23460744]
  157. Front Immunol. 2016 Aug 12;7:302 [PMID: 27570525]
  158. Biochim Biophys Acta. 2016 Jun;1863(6 Pt B):1427-35 [PMID: 26643254]
  159. Front Immunol. 2014 Oct 21;5:508 [PMID: 25374568]
  160. Int J Cancer. 2019 Jan 1;144(1):136-149 [PMID: 30121947]
  161. Front Immunol. 2020 May 15;11:938 [PMID: 32499785]

MeSH Term

Animals
Carcinogenesis
Humans
Molecular Targeted Therapy
Neoplasms
Neutrophils
Tumor Microenvironment
Journal Article Review
Article has an altmetric score of 8

Word Cloud

Created with Highcharts 10.0.0cancerneutrophilstumorigenesisNeutrophilstumormicroenvironmentTANsablemetastasistherapeuticTANfunctionsNeutrophils-onceconsideredsimplekillerspathogensunexcitingresearch-arenowacknowledgedroleprocessrecruitedturntumor-associatedinitiatepromoteprogressionConverselyanti-tumorigenicpropertiesdocumentedhighlightingversatilenaturehighpleiotropicplasticitypolymorphonuclearleukocytesPMN-LdissectambivalentrolesfocusselectedfunctionalaspectstargetsIndeedcriticalpointtargetingliesfactimmunosuppressivestateinducedresultingunwantedsideeffectsdeeperknowledgemechanismslinkeddiversedifferenttypesnecessarydefineappropriatestrategiesinducemaintainanti-tumorTumorigenesis:MissingTargetsSuccessfulNextGenerationCancerTherapies?immunotherapy

Similar Articles

Cited By